Skip to main content
Premium Trial:

Request an Annual Quote

Gyros Protein Technologies, Luxembourg Bio Technologies Ink Distribution Deal

This story has been updated to clarify the terms of the companies' distribution agreement.

NEW YORK (GenomeWeb) – Gyros Protein Technologies announced today that it has signed an agreement to distribute certain of Luxembourg Bio Technologies' coupling agents for peptide synthesis.

Under the terms of the deal, Gyros will have the exclusive rights to sell Luxembourg Bio Technologies' PyOxim and K-Oxyma in North America, and the nonexclusive rights to offer the reagents in the rest of the world. It will also have nonexclusive rights to sell Luxembourg Bio Technologies' HDMA worldwide.

Gyros said that it will market the reagents as part of its PurePep line of coupling agents. Additional terms were not disclosed.

In early 2016, immunoassay firm Gyros merged with peptide synthesis company Protein Technologies to form Gyros Protein Technologies.